Abstract：Hepatocellular carcinoma (HCC) is one of the most common malignancy tumors and and the incidence and mortality
of liver cancer in our country both rank first in the world. At present, the treatment methods for HCC are diverse, including surgical
treatment (hepatectomy, liver transplantation), local ablation therapy, interventional therapy, radiation therapy, immunotherapy, targeted
therapy, and chemotherapy.But these treatments both have requirements for the liver function of patients, because these treatments
may cause damage to the liver function of patients with liver cancer more or less, and some patients with liver cancer are already at
an advanced stage when they are discovered, and they already have liver damage. Therefore, it is very necessary to establish a simple
and effective model that can evaluate the liver function of patients with liver cancer to guide its clinical efficacy and prognosis.
Child⁃Pugh score is the most commonly used clinical method to evaluate liver function currently, and it has been already included
in the BCLC staging system to guide the clinical treatment and prognosis of patients with liver cancer. However, it contains five
indicators, albumin, total bilirubin, hepatic encephalopathy, ascites, and prothrombin time, they are not weighted, and ascites and hepatic
encephalopathy are highly subjective. In addition, Albumin and ascites are also factors that affect each other, thereby reducing the
objectivity and accuracy of the score. Albumin⁃bilirubin（ALBI）grade is a new method proposed in recent years to assess liver function.
It only contains two objective indicators of albumin and bilirubin, which is simpler and more objective than Child⁃Pugh score. The
specific calculation formula is ALBI=(log10 bilirubin×0.66)+(albumin×⁃0.085). According to the score, the patients with liver cancer
are divided into three grades, ALBI grade 1: ALBI≤⁃2.60, ALBI grade 2: ⁃2.60⁃1.39, the higher
the grade, the worse the liver function. In recent years, the role of ALBI grade in evaluating the efficacy and prognosis of patients
with liver cancer has been universally verified. This review summarizes the research progress of ALBI grade in evaluating efficacy
and prognosis of patients with liver cancer through liver transplantation, liver resection, liver radiofrequency ablation, hepatic artery
chemoembolization and targeted therapy, and immunotherapy, as well as the combination of ALBI grade and other staging systems
to assess the prognosis of patients with liver cancer
李 曦，商 消，马筱慧，王楠娅. 白蛋白‐胆红素分级评估肝癌患者疗效和预后的
研究进展[J]. 肿瘤代谢与营养电子杂志, 2021, 8(5): 558-563.
Li Xi, Shang Xiao, Ma Xiaohui, Wang Nanya. Research progress of albumin‑bilirubin grade in evaluating efficacy and prognosis of patients with hepatocellular carcinoma. Electron J Metab Nutr Cancer, 2021, 8(5): 558-563.
